Janus Henderson Group plc Reports New 5.3% Stake in Tarsus Pharmaceuticals, Inc.

Janus Henderson Group plc filed a Schedule 13G on May 15, 2026, reporting a new 5.3% stake in Tarsus Pharmaceuticals, Inc. (TARS). As of the event date on March 31, 2026, the firm beneficially owns 2,240,963 shares of common stock. Janus Henderson Group plc serves as the ultimate parent company for several SEC-registered investment advisers, including Janus Henderson Investors US LLC and Janus Henderson Investors UK Limited, which exercise investment and voting discretion over managed portfolios. The filing indicates that the shares are held in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. The reporting person reported shared voting and shared dispositive power over the entire position of 2,240,963 shares. No individual managed portfolio was reported to own more than 5% of the outstanding common stock. This filing marks an increase from a previously reported 0.0% ownership position.